Clinical Trial Detail

NCT ID NCT02500199
Title Phase I Study of Pyrotinib in Patients With HER2-positive Solid Tumors
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Hengrui Therapeutics, Inc.
Indications

lung non-small cell carcinoma

Her2-receptor positive breast cancer

Advanced Solid Tumor

stomach cancer

Therapies

Pyrotinib

Age Groups: adult senior

Additional content available in CKB BOOST